A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

Conditions

• Episodic Migraine

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Botulinum toxin type A — BIOLOGICAL
  Dose "A" U /Injection (U/I) , Intramuscular (IM) on every 12 weeks during a period of 36 weeks with a total of 4 injections.
• Botulinum toxin type A — BIOLOGICAL
  Dose "B" U/I, IM on every 12 weeks during a period of 36 weeks with a total of 4 injections.
• Placebo — OTHER
  "0" U/I, IM on Day 1 and Week 12 with a total of 2 injections.
• Botulinum toxin type A — BIOLOGICAL
  Dose "A" U/I, IM on Week 24 and Week 36 with a total of 2 injections.
• Botulinum toxin type A — BIOLOGICAL
  Dose "B" U/I, IM on Week 24 and Week 36 with a total of 2 injections.

Study Details

The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing episodic migraine. A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head, and is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Episodic Migraine is defined as having less than 15 days of headache a month with at least 6 days with migraine headaches. Migraines are caused by a series of events which cause the brain to get stimulated / activated, which results in the release of chemicals that cause pain. Dysport® is a formulation of Botulinum toxin type A (BoNT-A), a medication that stops the release of these chemical messengers. The study will consist of 3 periods: 1. A 'screening period' of 6 to 12 weeks to assess whether the participant can take part to the study and requires 1 visit. 2. A first Treatment Phase of 24 weeks. On Day 1 and at Week 12 of the first Treatment Phase, participants will receive injections into various muscles across the head, neck, face and shoulders. The injections will contain either a dose "A" or a dose ''B'' of Dysport® or a placebo (an inactive substance or treatment that looks the same as, and is given in the same way as, an active drug or intervention/treatment being studied). Participants will make 4 visits to the clinic in person and have 4 remote (online) visits. 3. A second Treatment Phase of 24 weeks (extension phase). At Week 24 and at Week 36, all participants will get Dysport® (dose "A" or dose "B"). There will be 3 in person visits and 4 remote visits. Participants will need to complete an e-diary and questionnaires throughout the study. Participants will undergo blood samplings, urine collections, physical examinations, and clinical evaluations. They may continue some other medications, but the details need to be recorded. The total study duration for a participant will be up to 60 weeks (approx. 14 months).

Key Dates

First listed

Sep 21, 2023

Start date

Sep 29, 2023

Status verified

Sep 2026

Primary completion

Jun 1, 2026

Completion

Nov 16, 2026

Study Design

Enrollment

751 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Arms

• Experimental: Dysport® dose "A"
  Participant will receive four treatment cycles, each separated by an interval of 12 weeks. Double-blind placebo-controlled (DBPC) Phase: Dysport® dose "A" administered intramuscularly on Day 1 and Week 12. Extension Phase: Dysport® dose "A" administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48)
• Experimental: Dysport® dose "B"
  Participant will receive four treatment cycles, each separated by an interval of 12 weeks. DBPC Phase: Dysport® dose "B" administered intramuscularly on Day 1 and Week 12. Extension Phase: Dysport® dose "B" administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48)
• Placebo Comparator: Placebo - Dysport dose "A"
  Participant will receive four treatment cycles, each separated by an interval of 12 weeks. DBPC Phase: Placebo dose "A" administered intramuscularly on Day 1 and Week 12. Extension Phase: Dysport® dose "A" administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48).
• Placebo Comparator: Placebo - Dysport dose "B"
  Participant will receive four treatment cycles, each separated by an interval of 12 weeks. DBPC Phase: Placebo dose "B" administered intramuscularly on Day 1 and Week 12. Extension Phase: Dysport® dose "B" administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48).

Primary Outcome Measure

Change from baseline in monthly migraine days (MMD) [ Time Frame: Every 4 weeks from Week 4 (Weeks 1-4) to Week 24 (Weeks 21-24) ]

Locations (66)

Find similar trials in Birmingham, AL

Related Studies

• A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
  PHASE3 · Recruiting · AbbVie · Huntsville, Alabama
• Efficacy of Nerve Blocks for Episodic Migraine
  PHASE2 · Recruiting · Mayo Clinic · Rochester, Minnesota
• A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
  PHASE3 · Recruiting · H. Lundbeck A/S · Stamford, Connecticut
• Chiropractic Care for Episodic Migraine
  Recruiting · Brigham and Women's Hospital · Boston, Massachusetts